Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-25. (previously cancelled).

26. (cancelled without prejudice).

27. (currently amended) The method as claimed in claim [26] 41, wherein in said administration of said composition, said composition further comprises at least one of:

a hypouricemic agent, wherein said hypouricemic agent is centella asiatica purified triterpenes;

a radical scavenger agent, wherin said radical scavenger agent is selenium;

a sympatholytic agent, wherein said sympatholytic agent is yohimbine;

a sympathicomimetic agent, wherein said sympathicomimetic agent is from the group consisting of phendimetrazine bitartrate and phendimetrazinum pamoate; and

at least one vitamin, wherein said at least on vitamin being selected from the group consisting of vitamin A, vitamin B1, vitamin B6, vitamin E and Vitamin C.

28. (previously added)The method as claimed in claim 27, wherein in said administration of said composition, said composition further comprises at least one diet adjuvant selected from the group consisting of sedative-ansiolytic agents, anoretic agents and lipolytic agents.

29. (currently amended) The method as claimed in claim [26] 41, wherein in said administration of said composition, said benfluorex is present in amount from 7% to 23% in weight of the total amount of the composition;

said pancreatine IX F.U. is present in an amount from 27% to 43% in weight of the total amount of the composition;

said metformine is present in an amount from 36% to 41% in weight of the total amount of the composition; and

said Na dehydrocloate is present in an amount from 9% to 14% of the total amount of the composition.

30. (currently amended) The method as claimed in claim [26] 41, wherein in said administration of said composition,

said benfluorex is present in an amount from 7% to 23% in weight of the total amount of the composition;

said pancreatine IX F.U. is present in an amount from 27% to 43% in weight of the total amount of the composition;

said metformine is present in an amount from 36% to 41% in

weight of the total amount of the composition; and

said Ursodesoxycolic acid is present in an amount from 14% to 17% in weight of the total amount of the composition.

31. (previously amended) The method as claimed in claim 27, wherein in said administration of said composition, each of said elements of said composition are in a ratio of weight with respect to the total weight of said composition wherein,

said centella asiatica purified triterpenes is in a ratio from 0.04:1 to 0.5:1 in weight with respect to said total weight of composition;

said selenium is in a ratio from 0.09:1 to 0.3:1 in weight with respect to said total weight of composition;

said yohimbine is in a ratio from 0.0009:1 to 0.0007:1 in weight with respect to said total weight of composition;

said phendimetrazine bitartarate or phendimetrazine pamoate is in a ratio from 0.004:1 to 0.13:1 in weight with respect to said total weight of composition;

said vitamin A is in a ratio from 0.5:1 to 1.8:1 in weight with respect to said total weight of composition;

said vitamin B1, is in a ratio from 0.002:1 to 0.2:1 in weight with respect to said total weight of composition;

said vitamin B6, is in a ratio from 0.05:1 to 0.2:1 in weight with respect to said total weight of composition;

said vitamin E, is in a ratio from 0.09:1 to 1:1 in weight with respect to said total weight of composition; and

said vitamin C, is in a ratio from 0.09:1 to 0.3:1 in weight with respect to the total weight of composition.

32. (currently amended) The method as claim in claim 28, wherein in said administration of said composition, each of said elements of said composition are in a ratio of weight with respect to the total weight of the composition wherein ;

said sedative-ansiolityc agent is the benzodiazepine dipotassium chlorazepate in a ratio from 0.0005:1 to 0.03:1 in weight with respect to the total weight of composition;

said anoretic agent is selected from the group consisting of diethylpropione chlorhydrate, fenfluramine chlorhydrate, D-fenfluramine chlorhydrate, said anorectic agent being present in a ratio from 0.002:1 to 1.3:1 in weight with respect to said total weight of composition; and

said lipolityc agent is [selected from the group consisting of] triiodiotiroacetic acid [and any tiroxine analogs] which is present in a ratio from 0.0002:1 to 0.003:1 in weight with respect to said total weigh of composition.

33. (currently amended) The method as claimed in claim [26] 41, wherein said administration of said composition is performed orally in doses from 7g to 23g per day to a patient of the weight of approximately 70kg.

34. (previously added)The method as claimed in claim 27, wherein said administration of said composition is performed orally in doses from 7g to 23g per day to

a patient of the weight of approximately 70kg.

35. (previously added)The method as claimed in claim 28, wherein said administration of said composition is performed orally in doses from 7g to 23g per day to a patient of the weight of approximately 70kg.

36. (previously added)The method as claimed in claim 29, wherein said administration of said composition is performed orally in doses from 7g to 23g per day to a patient of the weight of approximately 70kg.

37. (previously added)The method as claimed in claim 30, wherein said administration of said composition is performed orally in doses from 7g to 23g per day to a patient of the weight of approximately 70kg.

38. (previously added)The method as claimed in claim 31, wherein said administration of said composition is performed orally in doses from 7g to 23g per day to a patient of the weight of approximately 70kg.

39. (previously added)The method as claimed in claim 32, wherein said administration of said composition is performed orally in doses from 7g to 23g per day to a patient of the weight of approximately 70kg.

40. (withdrawn for consideration)

41. (currently added) A dietary weight loss method, comprising the steps of:

substantially reducing or eliminating from a person's diet all carbohydrate-based foods;

administering a composition of a plurality of agents that produce a synergistic effect of reducing the concentration of a plurality of internal body chemicals, where said composition is comprised of;

a hypocholesterolemic agent, wherein said hypocholesterolemic agent is selected from the group consisting of benfluorex and ursodesoxycolic acid;

a hypotriglyceride agent, wherein said hypotriglyceride agent is benfluorex;

a lipasic and proteasic agent, wherein said lipasic and proteasic agent is pancreatine IX F.U.;

a hypoglycemic agent, wherein said hypoglycemic agent is metformine; and

a hydrocoleretic agent, wherein said hydrocoleretic agent is selected from the group consisting of Na dehydrocloatye and ursodesoxycolic acid.

42. (currently added) A dietary weight loss method according to claim 41, wherein said method further comprises the step of after reducing or eliminating all carbohydrate-based foods, replacing said carbohydrate-based foods with foods obtained using a food composition in the form of a flour having no more than 20% carbohydrates by weight.

43. (currently added) A dietary weight loss method according to claim 42, wherein said method further comprises the step of, after replacing said carbohydrate-based foods with foods obtained using a food composition in the form of a flour having no more than 20% carbohydrates by weight, determining is said person is suffering from the effects from the weight loss method.

44. (currently added) Method for treating persons subjected to or having being subjected to a ketogenic diet and who suffer from side effect of a diet, comprising administering a composition of a plurality of agents that produces a synergistic effect of reducing concentration of a plurality of internal body chemicals, wherein the composition is comprised of,

a hypocholesterolemic agent, wherein said hypocholesterolemic agent is selected from the group consisting of benfluorex and ursodesoxycolic acid;

a hypotriglyceride agent, wherein said hypotriglyceride agent is benfluorex;

a lipasic and proteasic agent, wherein said lipasic and proteasic agent is pancreatine IX F.U.;

a hypoglycemic agent, wherein said hypoglycemic agent is metformine; and

a hydrocoleretic agent, wherein said hydrocoleretic agent is selected from the group consisting of Na dehydrocloatye and ursodesoxycolic acid.